In conclusion, multiple studies across different tumor types have demonstrated that higher levels of CD169-expressing macrophages in TDLNs correlate positively with better disease prognosis, highlighting the potential significance of these specialized macrophages in anti-tumor responses. This evidence concerns the gene SIGLEC1 and neoplasm.